AR030529A1 - Derivados de acido 2- acetidincarboxilico, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar un medicamento - Google Patents

Derivados de acido 2- acetidincarboxilico, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar un medicamento

Info

Publication number
AR030529A1
AR030529A1 ARP000103483A ARP000103483A AR030529A1 AR 030529 A1 AR030529 A1 AR 030529A1 AR P000103483 A ARP000103483 A AR P000103483A AR P000103483 A ARP000103483 A AR P000103483A AR 030529 A1 AR030529 A1 AR 030529A1
Authority
AR
Argentina
Prior art keywords
alkyl
branched
group
substituted phenyl
ring
Prior art date
Application number
ARP000103483A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR030529A1 publication Critical patent/AR030529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de ácido 2-acetidincarboxílico neurotrofico, caracterizados porque comprenden un compuesto de la formula (1) o una sal farmacéuticamente aceptable de ella, donde (a) R1 se selecciona del grupo que consiste en: (i) COCOR2, donde R2 es un alquilo ramificado o derecho de (C1-6), alquenilo ramificado o derecho de (C2-6), cicloalquilo de (C5-7), 2-tienilo, 3-tienilo, fenilo o fenilo sustituido (el anillo de fenilo sustituido posee de uno a tres sustituyentes seleccionados en forma independiente del grupo que consiste en alquilo inferior, alcoxi inferior, hidroxi y halogeno), (ii) CONHR3, donde R3 es alquilo ramificado o derecho de (C1-6), (iii) SO2R4, donde R4 es fenilalquilo o fenilalquilo sustituido (el anillo de fenilo sustituido posee de uno a tres sustituyentes seleccionados en forma independiente del grupo que consiste en alquilo inferior, alcoxi inferior, hidroxi y halogeno), (iv) un heterociclo de formula (2) donde la porcion del anillo del mismo es aromático y contiene opcionalmente uno o más heteroátomos seleccionados del grupo que consiste en oxígeno, sulfuro y nitrogeno; (b) X e Y son (i) C=O u (ii) O o NR5 (donde R5 es alquilo ramificado o derecho de (C1-6)), respectivamente, o en forma alternativa juntos forman un anillo de tetrazol 1,5-disustituido; (a) Z es un alquilo ramificado o derecho de (C1-5) o alquenilo sustituido en una o más posiciones con Ar, donde Ar se selecciona del grupo que consiste en 2-piridil, 3-pridil, 4-piridil, fenilo y fenilo sustituido (el anillo de fenilo sustituido tiene desde uno hasta tres sustituyentes seleccionados en forma independiente de alquilo inferior, alcoxi inferior, hidroxi y halogeno), con la condicion de que Z y R2 no pueden ser ambos alquilo de C1; y (b) A es X-Y-Z o hidrogeno. También suministra composiciones farmacéuticas que comprenden lo mismos; usos de los mismos para preparar medicamentos para tratar y prevenir trastornos caracterizados por dano neuronal.
ARP000103483A 1999-07-09 2000-07-07 Derivados de acido 2- acetidincarboxilico, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar un medicamento AR030529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14300199P 1999-07-09 1999-07-09

Publications (1)

Publication Number Publication Date
AR030529A1 true AR030529A1 (es) 2003-08-27

Family

ID=22502144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103483A AR030529A1 (es) 1999-07-09 2000-07-07 Derivados de acido 2- acetidincarboxilico, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar un medicamento

Country Status (4)

Country Link
US (1) US6544976B1 (es)
AR (1) AR030529A1 (es)
AU (1) AU5483500A (es)
WO (1) WO2001004091A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
DE60204046T2 (de) 2001-10-04 2006-01-19 Ortho-Mcneil Pharmaceutical, Inc. N-heterocyclylhydrazide als neurotrophe mittel
MX2007007553A (es) * 2004-12-24 2007-08-15 Prosidion Ltd Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes.
WO2008135525A2 (en) * 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted azetidines, manufacturing and use thereof as medicaments
EP2443107B1 (en) * 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
CA2102180C (en) * 1991-05-09 2002-07-23 David M. Armistead Novel immunosuppressive pyrrolidine/piperidine/azepane-2-carboxylic acid derivatives
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
IL107184A (en) * 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5786378A (en) 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
AR010744A1 (es) 1996-12-09 2000-07-12 Guildford Pharmaceuticals Inc Inhibidores polipropilos de ciclofilina
US5935989A (en) 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
US5874449A (en) 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
ZA98825B (en) 1997-02-27 1998-10-19 Guilford Pharm Inc Method of using neurotrophic carbamates and ureas
US5846979A (en) 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
ATE262519T1 (de) * 1997-12-19 2004-04-15 Abbott Lab Heterozyklische ether- und thioether-verbindungen,verwendbar zur steuerung von chemischer synaptischer transmission
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
US6544976B1 (en) 2003-04-08
WO2001004091A1 (en) 2001-01-18
AU5483500A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
DK2207770T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
UY28132A1 (es) Derivados de pirrolopirimidina
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
HUP0402313A2 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
KR950704304A (ko) 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives)
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
DK1178982T3 (da) Heterocykliske, substituerede aminoazacykliske forbindelser, der er nyttige som midler til centralnervesystemet
UY25332A1 (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO324219B1 (no) Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom
AR030529A1 (es) Derivados de acido 2- acetidincarboxilico, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar un medicamento
PE20091079A1 (es) Compuestos heterociclicos como moduladores npy y2
AR044014A1 (es) Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas
KR950032147A (ko) 아실화된 아미노알칸이미다졸 및 -트리아졸
UA74341C2 (uk) Похідні борелідину, які інгібують ангіогенез
AR029897A1 (es) Derivados de ciclobuteno, composiciones farmaceuticas y uso de los derivados para preparar medicamentos
KR970702845A (ko) 신규의 히드록시믹산 유도체, 그를 포함한 약제학적 조성물 및 그의 제조방법
DE60003671D1 (de) Halo-derivate von 9-deoxo-9a-aza-9a-homerythromycin a
AR009144A1 (es) Compuestos heterociclicos guanidilamino, composicion farmaceutica que comprende dicho compuesto y uso del mismo para la fabricacion de un medicamento
DE3764667D1 (de) Substituierte carbonsaeureamide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
FI935690A0 (fi) Oralt aktiva antivirala foereningar
AR012030A1 (es) Derivados de 1-acil-1,2-dihidroquinolina 2-substituida, el uso de los mismos para la fabricacion de un medicamento y una composicion farmaceutica.
GT200100120A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal

Legal Events

Date Code Title Description
FB Suspension of granting procedure